Description
Title: Early Alzheimer’s Disease and Zinc Therapy: Safety and Potential Therapeutic Efficacy
Abstract: Wilson disease (WD), an inherited condition marked by elevated levels of non-ceruloplasmin bound (‘free’) copper in serum and urine, is typically treated with zinc therapy. Alzheimer’s disease (AD) or its prodromal form has a subset of patients known as as Mild Cognitive Impairment (MCI), have higher than average levels of non-ceruloplasmin copper, and are unable to maintain a normal copper metabolic balance. Zinc works by inducing intestinal cell metallothionein, which prevents the body from absorbing copper from the intestinal tract and restores normal levels of non-ceruloplasmin copper. It is used in WD because of this. Even though the studies missed their primary endpoints due to study design and other significant flaws, zinc therapy has shown potential positive effects in early AD clinical trials. Nevertheless, zinc showed promise for improved cognitive performance in the AD patients who were studied by reducing non-ceruloplasmin copper levels. no significant side effects The safety of zinc therapy is discussed in this review, as well as any potential therapeutic benefits that might be anticipated for a subset of people who exhibit both cognitive complaints and signs of copper deficiency.
Keywords: zinc therapy; mild cognitive impairment; Alzheimer’s disease; Wilson disease safety; efficacy; copper
Paper Quality: SCOPUS / Web of Science Level Research Paper
Subject: Biomolecules
Writer Experience: 20+ Years
Plagiarism Report: Turnitin Plagiarism Report will be less than 10%
Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.
What will I get after the purchase?
A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.
In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915
Reviews
There are no reviews yet.